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Clonal evolution is involved in the progression of chronic lymphocytic leukemia (CLL). To link 
evolutionary patterns to different disease courses, we performed a long-term longitudinal 
mutation profiling study of CLL patients. Tracking somatic mutations and their changes in allele 
frequency over time and assessing the underlying cancer cell fraction revealed highly distinct 
evolutionary patterns. Surprisingly, in long-term stable disease and in relapse after long-lasting 
clinical response to treatment, clonal shifts are minor. In contrast, in refractory disease major 
clonal shifts occur although there is little impact on leukemia cell counts. As this striking pattern 
in refractory cases is not linked to a strong contribution of known CLL driver genes, the 
evolution is mostly driven by treatment-induced selection of sub-clones, underlining the need for 
novel, non-genotoxic treatment regimens. 
Introduction 
Cancer can be conceptualized as an evolutionary process within a given organism 1, 2. By 
increasing the fitness of cancer cells, mutations enable sub-clones to outcompete non-malignant 
cells and less adapted cancer cell clones. Furthermore, clonal evolution allows selection of cell 
populations that are resistant to therapy or responsible for disease recurrence. For some tumor 
entities like acute myeloid leukemia (AML), the concept of cancer initiating cells seems to 
account for tumor relapses without further genetic evolution. For other malignancies however, it 
is more likely that additional mutations play a crucial role in tumor recurrence. This is also true 
for chronic lymphocytic leukemia (CLL), where progression and clonal evolution has been 
analyzed in the context of treatment induced genetic changes 3, 4. 
Clinically, CLL is characterized by a highly variable course. The survival time of patients varies 
between months and decades. Often patients remain untreated for many years until clinical 
symptoms require therapeutic intervention 5. Despite high rates of initial treatment response, a 
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major clinical challenge is the occurrence of refractory disease that does not respond to treatment. 
Refractory cases are often characterized by a deletion and/or a mutation in the tumor suppressor 
gene TP53 located on the short arm of chromosome 17 (del17p/TP53mut). Although a number of 
recurrently mutated genes were identified in CLL that are of prognostic relevance 4, 6-9 
del17p/TP53mut remains the strongest adverse prognostic factor for progression-free and overall 
survival in CLL 4, 10, 11. The incidence of mutated or deleted TP53 is below 3% in Binet A stage 
CLL representing cases with good prognosis or in the pre-malignant monoclonal B-cell 
lymphocytosis (MBL) state, but increases to 12% at time of first treatment initiation, and to more 
than 37% in chemotherapy refractory cohorts 8, 12, 13. Despite this increase in cases with mutated 
or deleted TP53 at later disease stages, clonal evolution has been considered rare in CLL. 
Early cytogenetic and molecular cytogenetic studies reported unequivocal evidence for 
occurrence of clonal evolution in CLL, albeit rare 14-17. More recently, high-resolution microarray 
and next-generation-sequencing (NGS) based approaches were applied to track subclonal 
heterogeneity and clonal evolution in CLL. Based on a SNP micro-array analysis of pretreatment 
and relapsed samples from 42 patients, DNA copy number variations (CNVs) were reported that 
expand or newly occur at relapse 18. The respective genomic regions contain candidate driver 
genes of relapse and/or chemotherapy resistance. Somatic mutation profiling of CLL by NGS 
revealed recurrent gene alterations 19 and confirmed molecular heterogeneity 20. The 
comprehensive analysis of 149 CLL cases allowed to distinguish clonal (MYD88, trisomy 12, and 
del(13q)) and subclonal (SF3B1 and TP53) driver mutations 20 and this order was validated by the 
same group in a huge clinical study 4. While a considerable number of driver genes and recurrent 
genomic alterations were identified via WES analysis of a cumulative number of more than 1000 
CLL patients, there are only few studies deciphering changes of drivers over the course of 
disease. Mutation profiling of 3 CLL patients over time indicated heterogeneous clonal evolution 
patterns 21. By a similar approach, 10 of 12 CLL cases treated with chemotherapy were shown to 
undergo evolution of sub-clones with respective driver mutations (SF3B1 and TP53), while this 
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was detected in only 1 of 6 cases that were not treated 22. While one study reported that clonal 
composition remained stable at disease progression and relapse 23 another study referred that 13 
of 28 sequentially sampled cases underwent genetic change of >20% with 9 of them (but none of 
the non-evolving cases) also display epigenetic evolution24.  
There was a number of deep sequencing studies focusing on a targeted panel for candidate genes 
in CLL providing evidence of clonal outgrowth over time i.e. of TP53 after treatment25-27. 
Despite that, the major focus here was on untreated patient samples and the response to therapy 
was not considered as a predictor of evolution. In addition, targeted analysis of a restricted 
number of drivers can give an idea of clonal rigidity, but not show emergence and outgrowth of 
new subclones characterized by variants not covered with the panel. A similar approach 
considering aberrations in addition to known driver mutations deciphers the history of these 
alterations by integrating longitudinal and cross-sectional data in 70 patients 28. While the 
distinction of evolutionary early and late events showed a similar pattern to Landau et al, again 
the association with patient outcome has not been addressed.  The biggest whole exome 
sequenced cohort with sequential sampling in CLL included 59 patients from CLL8 with samples 
before and after relapse to FC/FCR showing changes of cell fractions characterized by specific 
drivers as well as linear versus branched evolution patterns in 57 of 59 cases 4. However, this 
group consisted only of relapsed cases with a missing control of refractory and long-term 
untreated patients. Due to the fact, that again type and duration of response were not considered 
as parameters, a link between treatment, outcome and dynamic genomic changes in CLL is barely 
explored. Although a connection of response to therapy and dynamic genomic changes is 
plausible, it remains unclear how clonal evolution is linked to long-term stable, to relapsed or to 
refractory disease.  
In order to elucidate the clonal evolution of CLL cell populations in the presence or absence of 
therapy, we performed a long-term longitudinal mutation profiling study of a multifarious cohort 
of CLL patients with a well annotated patient history.  
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Aberrant TP53 dictates the clinical course of the disease, it is a key driver of acquired resistance 
and potentially supersedes other parameters. Therefore, we excluded patients with del17p or 
mutated TP53 status at baseline as we presumed that these patients had acquired the most 
relevant evolution marker already. Samples were obtained at different time points before and 
after treatment in three different clinical groups: i) long-term untreated cases with stable disease 
and no need for treatment over at least 4 years, ii) relapsed cases with durable response to therapy 
of at least 2 years, and iii) refractory cases without response to treatment (SD, PD) or cases that 
progressed with requirement of a subsequent therapy within 1 year. Whole exome sequencing 
was performed and data were subsequently partially validated by targeted resequencing of 
identified mutations.  
Methods 
Sample collection 
We compiled an inventory of CLL patient samples before and after treatment and sequenced 
tumor and non-tumor control DNA (25 patients and 54 tumor samples including 21 patients with 
baseline samples prior to any therapy). Our inclusion criteria were: (i) no del17p or mutated TP53 
status at baseline (ii) patients fitting to any of the three groups (a) long-term untreated cases with 
stable disease and no need for treatment over at least 4 years, (b) relapsed cases with durable 
response to therapy of at least 2 years, and (c) refractory cases without response to treatment (SD, 
PD) or cases that progressed with requirement of a subsequent therapy within 1 year. 
All patients gave informed consent according to the Helsinki Declaration. Sample acquisition for 
sequencing purposes was approved by a local ethical review committee (Ethikkommision Ulm 
University, ethik-kommission@uni-ulm.de, 17.06.2008, 96/08-UBB/se). 
Peripheral blood mononuclear cell samples were enriched for tumor (CD19+) and normal CD19-
cells using MACS microbead cell separation (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Genomic DNA was isolated from unsorted and sorted CLL cells using All Prep Kit (Qiagen, 
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Hilden, Germany). Quality and quantity of the purified DNA were assessed with the Qubit 
dsDNA BR Assay Kit (Lifetech technologies, Carlsbad, CA). 
Sequencing 
Whole Exome Sequencing was performed on Illumina HiSeq 2000 machines. Exome libraries 
were created using the TruSeq Exome Library Prep Kit or Agilent SureSelect enrichment Human 
Exome V4 Kit according to manufacturer's protocols. Alignment and variant calling were 
performed as described in29. 
Allele frequency changes in patient groups 
Per patient SNVs with genotype change were identified and differences in alternative allele 
frequency (aAF) calculated between consecutive time points. aAFs were clustered per patient into 
six clusters to give each time point equal weight regardless of the number of SNVs detected. 
Each change in aAF was grouped according to the status (untreated, relapse, refractory) at the 
second time point. Differences in the distribution of the allele frequency changes between the 
three patient groups were identified using a bootstrapped Kolmogorov-Smirnov test with 
n=10000. 
CNV calling and calculation of absolute copy numbers 
Estimation of the copy number state based on the exome sequencing data was achieved using 
Varscan 2 on the target regions30. Absolute copy numbers were calculated following31.  
Calculation of cancer cell fraction 
Cancer cell fractions (CCFs) integrating sample purity (estimated by FACS), ploidy inferred from 
FISH, copy number states calculated from whole exome sequencing and allelic fraction and 
coverage of somatic variants were calculated for the patients with available germline samples 
following the approach outlined in 20.  
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Estimation of clonal composition by TrAP 
Changes in clonal tumor composition were calculated integrating the CCF at the respective time 
points using TrAP 32. 
Quantification of DNA methylation and estimation of correlation between time points 
DNA methylation from the first and second time point of 10 patient phases (3 long-term 
untreated, 2 relapsed and 5 refractory) was assessed by Illumina Infinium HumanMethylation450 
BeadChips according to the manufacturer’s protocol. 
Details on the individual approaches are further described in the supplementary methods. 
Results  
The clinical course of patients grouped into distinct phases 
The clonal evolution in malignant B-cell populations of CLL patients was studied by longitudinal 
analyses in a total of 25 patients and 54 tumor samples. For 21 patients, the baseline sample was 
obtained prior to any CLL therapy, whereas 4 additional patients were pretreated before 
enrollment in our study. A common case history in CLL can consist of different phases including 
an untreated phase with a watch and wait strategy in the beginning followed by one or more 
therapies with either durable or very short responses or even refractoriness to the ongoing 
treatment. We observed such clinical phases in our patients throughout their individual medical 
history. For example, some of the long-term untreated patients required therapy at a later stage 
(e.g. HU-1-06) and some patients with initially long-lasting response became refractory after a 
subsequent treatment (e.g. HU-1-11). Therefore, we divided the individual patient histories into 
different clinical phases rather than using a rigid division of patients into categories. Individuals 
can go through several of these phases with sampling at the beginning and at the end of each 
phase. Three clinical disease patterns were distinguished and in total we identified 29 phases: 6 
phases were evaluated as long-term untreated, 5 as relapsed after initially durable response to 
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therapy, and 18 as treatment refractory. Details of the clinical course of patients and patient 
phases including treatment, treatment response and sampling, as well as cytogenetic grouping and 
the IGHV mutation status are presented in supplementary tables 1-3 and in supplementary figure 
1.  
 
Increased mutation rate is associated with refractory disease 
Identification of mutations was performed by comparative whole exome sequencing of CD19+ 
enriched peripheral blood mononuclear cells (PBMC) and, as non-malignant control, the sorted 
CD19-negative fraction of PBMC from the same patient. Over the course of this longitudinal 
study, no IGHV status switch was identified. In IGHV mutated cases, the major IGHV clone did 
not change, and IGHV mutations and SNP fingerprinting were used to confirm sample identity.  
Based on limited material for sorting of non-neoplastic cells, for 19 of 25 patients a non-tumor 
control was available for mutation detection. Applying established algorithms 33 for the calling of 
single nucleotide variations (SNVs) and small insertions and deletion (Indels), we observed an 
average of 15.1 mutations per sample (range 2-36)(supplementary table 4-6). A prediction of the 
response to therapy was not possible based on mutation numbers, as samples taken before long 
lasting response to therapy and before refractory disease had similar numbers of mutations (11.3 
(range 1-30) and 15.8 (range 2-34) respectively p-value Mann-Whitney test p=0.36, figure 1A, 
B). Samples obtained before any therapy as well as post-therapeutic samples from relapsed 
patients had the lowest number with 13.5 (range 2-30) and 13.0 (range 6-25) mutations in 
contrast to refractory patients with 17.9 (range 4-36) mutations, respectively (figure 1B) (Kruskal 
Wallis test p-value= 0.30). We identified 1.5 known driver events per sample with the largest 
variation and highest number of SNVs/Indels in refractory CLL samples. All cases except HU-1-
08, HU-1-11, and HU-1-21 harbored SNVs/Indels in known or candidate CLL driver genes 4, 34. 
Indeed, candidates previously associated with adverse outcome like BIRC3, EGR2 and SAMHD 
were identified predominantly in refractory cases, but preceded good response to (chemo)therapy 
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and therefore did not determine outcome (e.g., patients HU-1-19 or HU-1-15). In addition, this 
study revealed genes that were so far not associated with CLL but were mutated in more than one 
of the analyzed patients: MC5R, MYH2, RFX7, ROBO2 and SLITRK5.  
 
Clonal evolution of leukemic cells is dominant in patients with refractory disease 
Clonal evolution was modeled on the basis of SNVs that were assessed in longitudinal sample 
collections. FISH analysis with a panel of diagnostic probes 10 in a subset of samples revealed 
near diploidy of the neoplastic cells. Interestingly, no changes in cytogenetic aberrations in long-
term untreated phases could be identified based on FISH data (supplementary table 1). Most 
patients retained their karyotype after treatment, but HU-1-19 acquired a deletion in chromosome 
17p. Since neoplastic B-cell content was generally higher than 80%, allele frequencies were used 
as basis for modeling evolution over time. To this aim, SNVs were identified that displayed 
variable allele frequencies (AFs) between the time points of molecular analysis. During long-term 
untreated phases, AFs remained stable, which is in accordance with an unchanged clonal 
composition. Although one might expect in tumors with relapse after therapy the occurrence of 
clonal evolution with the acquisition of new variants, we observed the opposite: such clinical 
phases show the same mutational landscapes both at baseline and at relapse, and major shifts in 
AFs occurred only exceptionally (figure 2). In sharp contrast, during phases of therapy 
refractoriness, we found dramatic alterations in clonal composition (figure 2, figure 3). Notably, 
in refractory phases these increases and reductions in AFs occurred within relatively short time 
intervals (median phase length: refractory 707 days, relapse 2395 days, untreated 2088 days, time 
span refractory phases vs. time span untreated, treated and relapsed Mann-Whitney test p= 
0.00014, supplementary table 1), that were particularly much shorter than the phases in stable or 
relapsed cases. The high degree of allele frequency changes and the short time window over 
which these changes occurred indicate marked dynamics in the clonal shift, often notable in 
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tumors that appeared clinically unaffected by therapy (i.e. without remission and subsequent 
regrowth). These clonal shifts clearly indicate a change in the clonal composition, and strikingly 
they occur mostly during refractory phases, i.e. during treatment that does not successfully affect 
the clinical outcome. 
We further quantified overall allele frequency changes in the three different groups of clinical 
phases independent of the further course of disease (figure 3, changes in AFs over time provided 
in supplementary figure 2). Clearly, a substantially higher variation of AFs is seen in the samples 
that reach the therapy refractory phase. Comparison of 28 subsequent time points in 25 patients 
identified significant differences in the allele frequency changes over time between different 
types of clinical phases, which indicates that the degree of change in the clonal composition is 
different in the three clinical groups (Kruskal-Wallis test p=0.00262, corrected based on 
permutation of phase labels). Furthermore, the untreated phases showed a significantly lower 
allele frequency change over time independent of the extent of time between sampling (p<0.01 
for untreated vs relapsed and untreated vs relapsed/refractory; supplementary table 7). 
 
Clonal expansion or reduction of individual sub-clones over time and with treatment 
Integrating tumor purity, copy number state (supplementary figure 3) and allele frequencies, we 
inferred the cancer cell fractions (CCF, supplementary table 8) affected by individual mutations 
as described before 4. In some patients and phases, known cancer drivers listed in the COSMIC 
mutation database could be linked to the changes in cancer cell fraction (supplementary figure 4, 
gene symbols from COSMIC highlighted in purple). For example, HU-1-13 showed a mutation 
in the cancer driver EGFR only in the untreated and refractory sample (CCF 7% coverage 33 and 
CCF 66%, coverage 57) (supplementary figure 4). The mutation was undetected (coverage 48) at 
relapse indicating a reduction of this clone below the detection limit at relapse. Furthermore, the 
fraction of cells carrying an ANO1 mutation steadily increased from 0% over 2.3% to 22.0% in 
the refractory sample (coverage 48, 42 and 41). Interestingly, the major clone present at the 
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relapse and characterized by an NLRP13 mutation (CCF 28.5%, coverage 21) was not detected 
any more in the refractory sample (coverage 25), indicating that this clone was lost during 
treatment or during progress. 
HU-1-19 displayed similar shifts albeit with a different clonal composition, but also with 
elimination of a clone after treatment. The EGR2 variant changed from 2.1% to 27% mutant 
allele frequency (CCF 4%, coverage 47 and CCF 55%, coverage 37) during the treatment-free 
interval, but dropped below the detection limit after first treatment (coverage 56). In addition, the 
major clone at the first time point characterized by MARK2 (CCF 37%, coverage 74) without 
treatment (“untreated”) was slightly less prominent at the second time point without treatment 
(CCF 34%, coverage 54) and undetectable after treatment (coverage 60). These observations 
indicate a gradual change in clonal composition during an untreated phase of six years and a 
significant clonal replacement after treatment. 
 
Refractory CLL is associated with a branched evolution of leukemic cells 
In order to group observed clonal changes into different patterns of evolution, we analyzed 
overall AF changes between all possible pairs of consecutive samples that we grouped into 
disease phases for different types of evolution. On the basis of time-dependent changes of CCF, 
when significant AF changes were unidirectional, these evolution patterns were classified as co-
evolution (also termed “linear evolution”) 22. In contrast, evolution was classified as “branched” 
when different significant changes concomitantly increased and decreased in CCF between 
consecutive samplings and were thus “bidirectional”.  
As depicted in figure 4A, we observed in the group of long-term untreated patients phases in the 
clinical course where substantial shifts in the clonal composition occurred only after treatment. 
These shifts resulted either in co-evolution of few sub-clones while other sub-clones were lost 
(e.g. HU-1-15), or a simultaneous decrease and increase of different subclones indicative of 
branched evolution. Long-term untreated phases display mainly co-evolution patterns (4 of 5), 
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while only one patient (HU-1-19), who required treatment after six years, followed a branched 
evolution pattern and became refractory to a subsequent treatment. In phases preceding relapse, 
co-evolution appeared less frequent (3 of 5). Instead, relapsed and refractory CLL showed a 
tendency towards more frequent branched evolution than untreated CLL (6 of 10 vs. 1 of 5, 
Fisher exact test p=0.28), a pattern that was e.g. observed in the relapsed and treatment refractory 
phases of a single patient (HU-1-13). Interestingly, this patient was treated with FCR 
(Fludarabine, Cyclophosphamide, Rituximab) in 2005 and in 2009 again achieving a complete 
response (CR) each time, but at the second time with shorter duration. The differences in 
evolution types shows a trend towards more branched evolution in relapsed and even more in 
refractory phases (figure 4B). To assess the dynamic on a cellular level we inferred the clonal 
composition based on the cancer cell fractions using TrAP (figure 5). Interestingly the major 
subclone at refractory time point in HU-1-19 (clone 3, 41.5% clone fraction) is already present to 
a minor extend at the second untreated time point (clone fraction 2.0%) whereas the major clone 
at the first time point further evolved gaining an additional set of mutations subdividing into 
clones 4, 5 and 6 (clone fraction of 13.7%, 21.3% and 10.5%). In contrast a clone (19.0% clone 
fraction) present at the second untreated time point defined by an EGR2 mutation is undetected at 
the other last time point. To confirm the evolutionary changes with an additional method, we 
performed epigenetic analysis of 20 samples corresponding to 10 phases. In line with the genetic 
data, large-scale evolution of methylation patterns was not present in any of the evaluated long-
term untreated (n = 3) and relapsed (n = 2) phases displaying clonal changes of linear type while 
3 of the 5 examined refractory phases featured profound changes in DNA methylation 
(supplementary figure 5). In all patients, even in the ones with few methylation changes, 
hypermethylation was concentrated in poised promoters and Polycomb-repressed regions, 
whereas hypomethylation occurred mostly in heterochromatin (data not shown; assignment of 
chromatin states was according to the published reference epigenome of CLL35).  In spite of this 
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common pattern, we could not identify any specific CpGs that consistently changed methylation 
status throughout different patients or phases.  
 
In summary, based on the patients analyzed here, the clonal evolution pattern seems to be linked 
to the disease phases, and increased changes in allele frequency and a branched evolution are 
significantly more frequent after treatment compared to untreated patient phases (figure 6).  
Discussion 
Medical history and disease course of patients with CLL is very individual. In this study, we 
examined whole exome sequencing data of CLL patients acquired at several time points during 
their disease and treatment course. Comparing consecutive samples from individual patients, we 
identified somatic mutations that were present in the leukemia cells and tracked over time the 
changes in allele frequency of these mutations and the underlying fraction of cancer cells that 
carried the respective mutations. By modelling the clonal composition using the software TrAP 
32, we discovered different clonal evolution patterns and disease progression courses that were 
linked to the treatment and response history of the patients (figure 5). From the mutations and 
clonal changes that occur during CLL disease progression, we draw the following conclusions 
with respect to groups of genes, but also more conceptually with respect to clonal composition 
and evolution over time.  
Recurrent mutations in genes were linked to CLL relapse in three different time and treatment 
dependent patterns 36. First, one subset of genes initially displays subclonal mutations that are 
enriched after therapy. In contrast, mutations in a second set of genes remained clonally stable 
upon relapse. Finally, mutations in a third set of genes that are stable in most patients show clonal 
enrichment only in rare cases. However, these groups of mutations were not linked to a clinical 
phenotype. Furthermore, exponential-like growth patterns were recently associated with a larger 
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number of CLL drivers and short time to first treatment 37. Of note, these data were derived from 
untreated CLL patients followed over time. In our patient cohort under the selective pressure of 
treatment, neither common genetic risk factors like IGHV or recurrent aberrations, nor variants or 
typically affected pathways are characteristic for a specific clinical course. And although the 
number of mutations increased slightly after treatment, this did not reflect or even predict 
outcome after therapy, nor did the number of (sub-)clones. Furthermore, clonal evolution was 
associated with treatment and indeed branched evolution was found more often in refractory 
cases, but not exclusively. These results reflect published data for relapsed cases after FCR 
therapy, which could also not link progression free survival to an evolution pattern after FC(R) 
therapy 4, 22. Dividing our patient groups in long term responder and refractory cases allowed us 
in contrast to prior attempts to match the duration of response to the extent of the clonal shift. 
Counterintuitively, clonal evolution that was mostly dynamic occurred primarily in patients who 
displayed refractory disease, i.e. where major changes in clonal evolution happened under the 
guise of a clinically stable or progressing disease. Therefore, what correlated most with the 
duration of response to treatment was a highly dynamic evolutionary change among sub-clones, 
and this change was directly associated with refractory disease. In contrast and unexpectedly, 
relapse after initially durable response occurred mostly with the same sub-clones. We identified 
three distinctly different courses of clonal evolution that occurred under distinctly different 
treatment and response patterns. In refractory cases, clonal composition changed dramatically 
upon treatment failure and in patients 2, 4, and 18 this happened within only 3 months of therapy. 
Furthermore, in refractory phases, change in clonal composition was often accompanied by a 
profound shift in the bulk DNA methylation profile of the tumor, most probably reflecting 
different methylation profiles of the competing clones rather than de novo methylation changes, 
as it was previously shown that established CLL clones are epigenetically stable and changes in 
DNA methylation are unlikely to occur without genetic evolution 24. As an example, patient HU-
1-23 did not gain any new mutations between the two timepoints of his refractory phase but 
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underwent selection of particular pre-existent CLL clones according to the branched genetic 
evolution model and this was also manifested by a shift in DNA methylation of the bulk tumor. 
For the clinician managing the patient, “hidden“ selection of a resistant clone is masked by a 
tumor with a seemingly stable clinical phenotype, i.e. with a persistent lymphadenopathy and 
leukocytosis. This dynamic clonal change suggests either an increased evolutionary capacity in 
these patients or simply the presence of at least one resilient clone. Importantly a selective 
pressure of therapy is necessary to induce or catalyze this clonal change as provided by the 
clinical course of patients 15 and 19. Both have a longterm untreated phase without marked 
evolution but a strong shift after becoming refractory. Therefore, neither the underlying risk 
factors, the natural disease biology nor the type of evolution, which is branched in untreated and 
refractory phase in both patients, reflects the clinical course while the extent of evolution does. 
Importantly, we could show in addition that this process occurs also independently of TP53 
mutations, i.e. in a cohort of CLL patients without TP53 aberrations before treatment. Thus, in 
these patients the clonal evolution is driven mostly by treatment that seems to select for resistant 
CLL clones. 
Thus, our key finding is the striking observation of a clonal turnover during therapy in those 
patients, who were considered treatment refractory and therefore are assumed to have a stable 
tumor load. 
In contrast, long-term untreated cases and late relapses are genomically stable, although they are 
observed over a much longer period of time. In the latter we found a remarkably stable genomic 
landscape considering that these patients received a therapy with a subsequent re-growing after a 
prolonged treatment-free interval. This stability is completely different to a tumor that is 
refractory and apparently unaffected by therapy, but in contrast displays a dramatic change in 
clonal composition. This opposing clinical and genomic phenotype at first appears 
counterintuitive. However, these different courses of clonal dynamics in relapsing and refractory 
patient phases could be explained by the preexistence of a resistant clone that after removal of the 
16 
 
bulk tumor by a treatment intervention will quickly grow out and fill the empty niche. If such 
resistant clones are absent, competition and outgrowth over time is still possible, so that the 
tumor regrows with an almost identical clonal composition. This finding mechanistically explains 
and underlines the relevance of the widely used clinical paradigm of repeating the previous 
treatment regimen when a good and long-lasting response is achieved: based on the same clonal 
composition at relapse, the clinician can expect another good response of the tumor to the 
treatment as the tumor has the same clonal composition as before the treatment. Interestingly, 
new treatment modalities like venetoclax may behave similarly due to the strong reduction of 
tumor load, comparable to chemotherapy: While patients treated with short and effective 
venetoclax containing combination therapies lack BCL2 mutations at relapse, refractoriness to a 
long lasting venetoclax treatment associates with the outgrowth of a BCL2 mutated clone 
displaying the same clonal shift towards drug resistance, that we observe here in chemotherapy 
refractory cases 38, 39. On the other hand, ibrutinib may cause a more decelerated clonal shift due 
to its slow debulking treatment effect and also only slowly emerging resistant clones (i.e. point 
mutations in BTK/PLCG2 40). 
 
In summary despite the small patient cohort (n=25 with 54 time points), we identified a link 
between changes in the variant allele frequency and changes in clonal architecture, both of which 
are linked with shortened time to further treatment, i.e. treatment resistance. We found clonal 
evolution to occur without strong contribution of known CLL driver genes. However, there is a 
dramatic difference in clonal evolution patterns between relapsed and refractory samples, which 
highlights the importance of the treatment-induced clonal changes in relation to treatment 
response. This intrinsic characteristic of CLL evolution underlines the relevance of comparing the 
benefits of treatment compared to the watch-and-wait strategy that has a very low clonal 
evolution rate. Furthermore, the substantial clonal evolution in refractory disease highlights the 
17 
 
need for novel, non-genotoxic treatment regimens with targeted therapy that are less likely to 





Sequencing data have been deposited at the European Genome-Phenome Archive hosted at the 
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Figure 1: SNVs and InDels in patients across phases 
A) Somatic single nucleotide variants (SNVs) and Insertionen/Deletionen (InDels) identified in 
CLL samples (SNVs in blue, Indels in green). Genes with recurrent (patients n>2) somatic SNVs 
and Indels identified in our study or CLL drivers from previously published CLL cohorts 
highlighted by black boxes (4,26, COSMIC 19/03/14). Only patients with matched control 
sample were considered. 
B) Each symbol shows the number of variants identified in one patient sample. Samples are 
grouped and colored in dependence of treatment and outcome of the subsequent phase. Black 
bars represent group means. 
Figure 2: Allele frequency changes during the clinical course of CLL patients  
Overall clinical phase is depicted by colored bars on top (green=untreated, yellow=relapsed after 
treatment, red=refractory to treatment). The individual treatments and disease progressions are 
depicted in the first row of each graph with gray bars representing treatment, while green, yellow, 
orange and red bars indicate the type of treatment response and disease progression. Richter 
transformation in HU-1-32 (blue) is highlighted in the second row, above the alternative allele 
frequencies. Allele frequency changes are colored based on hierarchical clustering of the 
trajectories following by identifying the six major clusters (R function cutree). Y-axis: indicates 
allele frequencies, x-axis: indicates time course in years. 
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Figure 3: Allele frequency changes across phases 
Between two consecutive samplings in a patient, changes in allele frequency of clustered somatic 
SNVs shown as circles. Circles are grouped according to the clinical phase at the second time 
point. To weigh each patient identically, regardless of the number of mutations, the changes in 
allele frequency of all SNVs were clustered into six groups per patient and the average of these 
groups is depicted resulting in six circles per patient phase. Black line represents phase mean. 
Statistical significance of allele frequency change differences between clinical phases was tested 
using Kruskal-Wallis test and p-value corrected using 100000 permutations of the phase labels 
for the six mutation clusters representing each patient (p= 0.00262).  
Figure 4: Changes in Cancer Cell Fractions and evolution types 
A) Evolution patterns in 12 patients. Probability distribution of the cancer cell fraction (CCF) for 
each somatic SNV revealed clonal (red) or subclonal (blue) SNVs (left side). The changes in 
CCF are depicted in the last column. Changes (a mutation with a change in CCF of greater than 
0.2 (delta CCF >0.2) with probability >0.5) are highlighted in green (increased CCF) or red 
(reduced CCF). On the basis of time dependent changes of CCF (right side), evolution patterns 
were considered as (unbranched) co-evolution (C) when significant changes were unidirectional 
(up or down), or branched (B) when significant changes were in both directions (up and down) 
indicating that a dominant clone is replaced by its siblings. Time between samplings is indicated 
in years at the top. B) Difference in occurrence of evolution types across clinical phases 
(coevolution = blue, branched evolution = brown). 
Figure 5: Clonal composition as inferred by TrAP 
Exemplary changes in clone fraction for individual patients across samplings. Clonal composition 
was estimated by applying TrAP on the cancer cell fraction calculated for individual SNVs. 
Different clones are represented by the respective colors and individual time points are indicated 
on the x axis. Highlighted with the respective gene symbols are inferred clones linked to a known 
cancer driver gene. Y axis represents clonal fraction of the individual clones identified for the 
best fit TrAP solution. 
Figure 6: Model of the clonal composition changes 
Model of the clonal composition changes in the three different treatment phases (longterm 
untreated, relapsed and treatment refractory). Black lines indicate lymphocyte counts as surrogate 
marker for tumor load. Arrows indicate times of treatment. The stacked barplot indicates clonal 








Alignment and variant calling 
Alignment and variant calling were performed as described in 1. In summary, paired-end 
DNA sequencing reads were mapped to the hg19 assembly (NCBI build 37.1, downloaded 
from the UCSC genome browser at http://genome.ucsc.edu/) of the human reference genome 
using BWA version 0.5.10 2 and processed with samtools (version 0.1.17) and Picard tools 
(version 1.61, http://broadinstitute.github.io/picard).  Single nucleotide variants (SNVs) and 
small insertions or deletions (indels) were identified based on our in-house analysis pipeline 
using samtools mpileup and bcftools. For patients without germline sample we called variants 
using samtools mpileup and bcftools. SNVs with a genotype quality lower than 80 and with 
no genotype change between consecutive samples were filtered.  
CNV calling and calculation of absolute copy numbers 
Estimation of the copy number state based on the exome sequencing data was achieved using 
Varscan 2 on the target regions 3. Counting the uniquely mapped reads, log2 ratios were 
calculated for all segments against the respective germline control. Absolute copy numbers 
were calculated following4. In summary, first the ploidy was identified manually based on the 
FISH results available (see supplementary figures 3, for depiction of the exome sequencing 
based log2 ratios in regions analyzed by FISH). Incorporating the clinically assessed sample 
purity measured using FACS, the log2 ratio derived from the read counts of the exome 
sequencing were transformed into absolute copy numbers for the respective segments of the 
individual genomes. 
Estimation of clonal composition by TrAP 
Changes in clonal tumor composition were calculated integrating the CCF at the respective 
time points using TrAP 5. In summary, the individual cancer cell fractions across samples per 
patient were hierarchically clustered (R: hclust, complete linkage). The CCF profiles were 
grouped into six clusters (R: cutree k=6). The resulting mean centroids for the six clusters 
across timepoints were used as input data for TrAP (datatype GAUSSIAN, the error is 
estimated based on a normal approximation, see 5 for details). For the cluster the median error 
was calculated for the TrAP based estimation of the subclonal tumor composition. From the 
possible solutions the solution with the best fit was selected for each patient.  
Quantification of DNA methylation and estimation of correlation between time points 
DNA from the first and second time point of 10 patient phases (3 long-term untreated, 2 
relapsed and 5 refractory) was bisulfite-converted using the EZ DNA Methylation Kit (Zymo 
Research) and then whole-genome amplified, fragmented and hybridized to Illumina Infinium 
HumanMethylation450 BeadChips according to the manufacturer’s protocol. After single-
base extension and staining, the BeadChips were scanned using an Illumina iScan reader. 
Quality control of the raw data, preprocessing and basic analysis were performed using 
R/Bioconductor with the RnBeads package 6. Illumina probes known to be cross-reactive or 
overlapping known SNPs 7 were excluded from analysis. This was also done for probes giving 
unreliable measurements as determined by the Greedycut algorithm implemented in RnBeads. 
The data from the remaining probes were subjected to background subtraction using the Noob 
method 8 and beta-mixture quantile normalization (BMIQ 9). In a subsequent step, probes of 
non-CpG context, probes binding to sequences on sex chromosomes and probes with low 
standard deviation were filtered out. The data obtained by the remaining probes were used in 
downstream analyses. Methylation levels of CpG sites were calculated as β-values (β = 
intensity of the methylated allele (M)/[intensity of the unmethylated allele (U) + intensity of 
the methylated allele (M) + 100]. For each patient, the shift in overall methylation was 
estimated by calculating the square of the Pearson correlation coefficient (R2) between time 
points using the 40,000 most variable probes in all available samples. Differential methylation 
analysis between time points for each of the patient groups was performed using the limma 
method as implemented in the RnBeads package. For downstream enrichment analyses, we 
used only differentially methylated CpGs with absolute difference in mean β-values of at least 
0.1 at FDR 0.05. Possible enrichment of hypomethylated and hypermethylated CpGs within 
particular chromatin states was assessed using the R/Bioconductor package LOLA (Locus 
Overlap Analysis)10 and published reference CLL epigenomes111. Before the analysis, the 
genomic coordinates of the reference chromatin state regions were lifted over from hg38 to 
hg19 using liftOver. Enrichment analyses at the individual patient level were performed using 
CpGs with absolute difference in β-values between the two time points of at least 0.3. 
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Suppl. table 5: 
Table of SNVs identified 
Suppl. table 6: 




Suppl. figure 1: Graphical representation of clinical course of analyzed patients.  
Three patients are lost to follow-up (HU-1-09, -13, -15). (Black	box:	sample	collection	for	
WES;		Grey		box:	under	treatment;	Red	box:	Death,	Green	box:	last	follow	up;	
Transparent	 boxes:	 therapy	 response	 (CR	 =	 complete	 response;	 PR:	 partial	 response;	
SD:	stable	disease;	PD:	progressive	disease)	and	Richter	syndrome	(=	Richter);	Therapy	
information:	 R	 =	 Rituximab;	 O	 =	 Ofatumumab;	 F	 =	 Fludarabin;	 C	 =	 Cyclophoshamid;	
CBL=Chlorambucil;	 B=Bendamustin;	 A=Alemtuzumab;	 M=Mitoxantron;	 CHOP	 =	
Cyclophosphamid	 +	 Doxorubicin	 +	 Vincristin	 +	 Prednisolon;	 MCP	 =	 Melphalan	 +	
Cyclophosphamid	 +	 Prednisolon;	 PCR	 =	 Rituximab	 +	 Pentostatin	 +	 Cyclophosphamid;	
RLB	 =	 Rituximab	 +	 Lenalidomide	 +	 Bendamustin;	 RBM=	 Rituximab	 +	 Bendamustin	 +	
Mitoxantron;	DBEAM	=	Dexamethason	+	Carmustin	+	Etoposid	+	AraC	+	Melphalan;	Ibr	=	






Suppl. figure 2: Scatter plot of variant allele frequency changes between consecutive time 
points. Known cancer and CLL driver genes (Landau et al. 2015, Bailey et al. 2018) are 
highlighted in lightred if their change in allele frequency is significant based on Fisher’s test 
on the reference and alternative allele counts other SNVs presented in blue. Excluded are 
SNVs which are in dbSNP, have a coverage below 20 or a higher frequency than 5 % in 1000 
genomes. Gray lines represent error bars for the allele frequency calculation estimated from 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Suppl. figure 3: Copy number estimation based on read counts from exome sequencing. First 
panel genome wide log2 ratio of tumor vs. control counts. Second panel copy number log2 
ratio plot for regions analyzed by FISH. Third panel presenting density of log2 ratio regions. 





























Suppl. figure 4: Changes in cancer cell fraction (CCF) with annotation of genes listed in the 
Catalogue of Somatic Mutations in Cancer (COSMIC). Significant changes in CCF are 
highlighted by red (reduced CCF) or green color (increased CCF). Genes represented in 



































































































































































































































































































































































Suppl. figure 5: Density contour plots of methylation values at two consecutive time points 
for long-term untreated, relapsed and refractory CLL cases. For each patient, the methylation 
values of the overall 40,000 most variable CpGs were used to calculate the square of the 
Pearson correlation coefficient (R2) between time points.	
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